. . . These new stringent rules will strongly impact the pipeline of scientific talent the NIH has provided the biopharm industry.
Howard A. Young, Ph.D.
Advertisement
Articles by Howard A. Young, Ph.D.
Advertisement
Latest Updated Articles
- Final Word: NIH-Biopharm Interactions and the New NIH Conflict-of-Interest Regulations
Published: June 1st 2005 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
FDA-Approved WAS Gene Therapy Hits Market in Nonprofit Model
2
Charles River Incubator Cohort to Accelerate CGT Development
3
FAQ: Shifts in FDA Regulations and Strategies in 2025
4
Two-Minute Mysteries: BioPharm Stories - Episode 2: The Costly Myth of Noninvasive Glucose Monitoring
5
